+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 21Years - 70Years
All Genders
ID07536061

Randomized, Double-Blind Study Evaluating SRP-1005 Effects by Dose Escalation in Adults with Huntingtons Disease

Led by Sarepta Therapeutics, Inc. · Updated on 2026-10-19

32

Participants Needed

5

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a first-in-human, multi-center trial to study the effects of SRP-1005 in adults diagnosed with Huntingtons disease HD. This phase 1 study aims to evaluate the treatments safety and how the body processes SRP-1005, a drug administered by subcutaneous injection. The trial involves participants at specific stages of HD to better understand the impact of this investigational medication. Participants are randomly assigned to one of four groups receiving different doses of SRP-1005 or a placebo. All treatments are given by subcutaneous injection, with the study designed to carefully monitor each dose level. This randomized, double-blind, placebo-controlled trial includes dose escalation to assess safety and the drugs behavior at various concentrations. During the study, participants will undergo regular assessments to monitor adverse events and measure SRP-1005 levels in plasma, urine, and cerebrospinal fluid. The trial includes lumbar punctures and MRI scans as part of safety and feasibility evaluations. The main focus is on tracking any treatment-related side effects through week 24, with additional monitoring of drug concentration up to day 17 and cerebrospinal fluid levels through week 24. Participants are expected to be involved for about six months, including safety follow-up.

CONDITIONS

Brief Title

A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease

Research Team

S

Sarepta Therapeutics Inc., For Clinical Trial Information, Select Option 4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here